论文部分内容阅读
目的 观察HEP方案治疗III、IV期非小细胞肺癌 (NSCLC)的疗效及不良反应。方法 羟喜树碱 (HCPT) 10mg/m2 静滴d1 -5;足叶乙甙 (VP -16) 10 0mg/m2 静滴d1 -3 ;顺铂 (DDP) 5 0mg/m2 静滴d1 -2 (伴水化和利尿 )。 3周为一周期 ,用药最少 2周期。结果 HEP方案有效率为 5 3 .5 %,对照组为 3 5 .7%。治疗组和对照组毒副反应发生率无明显差异。结论 HEP方案治疗III、IV期非小细胞肺癌 (NSCLC)有一定疗效 ,不良反应未明显增加 ,值得临床推广应用。
Objective To observe the efficacy and adverse reactions of HEP regimen in the treatment of stage III and IV non-small cell lung cancer (NSCLC). Methods HCPT (10mg / m2) d1-5, VP -16 (100mg / m2) d1-3, DDP (50mg / m2) (With hydration and diuresis). 3 weeks for a period of medication at least 2 cycles. Results The effective rate of HEP regimen was 53.5% and that of control group was 35.7%. There was no significant difference in the incidence of side effects between the treatment group and the control group. Conclusion The HEP regimen has a certain effect in the treatment of stage III and IV non-small cell lung cancer (NSCLC), with no significant increase in adverse reactions. It is worthy of clinical application.